Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Twin setbacks for grass pollen allergy projects in development by Asit Biotech and Allergy Therapeutics expose an existential crisis.
An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…
DBV plans to refile Viaskin Peanut in the third quarter, but things look all but smooth.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
DBV Technologies’ decision to pull its Viaskin Peanut filing leaves the door open for Aimmune Therapeutics to clean up.
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Alnylam has secured its first approval, but history suggests that launch will be far from easy.